News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
Drugs for worms and river blindness could treat breast cancer
Cheap drugs which treat parasitic worms and conditions such as river blindness could be used for women with a type of breast cancer that often fails to respond to standard therapies.
Drug combination controls breast cancer for over twice as long
A new drug delays the progression of advanced breast cancer by over twice as long when used in combination with standard treatment, compared to standard treatment alone, a major clinical trial shows.
World-first cancer drugs could work in larger group of patients
A pioneering class of drugs that target cancers with mutations in the BRCA breast cancer genes could also work against tumours with another type of genetic fault, a new study suggests.
‘Stem cell’ test could identify most aggressive breast cancers
Breast cancers cells that behave like adult stem cells are more likely to spread to other parts of the body, according to research.
New pathway identified for debilitating skin condition
ICR scientists have discovered that a type of signal within tumour cells is critical to the development of a rare and debilitating inherited skin condition.
ICR welcomes olaparib approval by European Medicines Agency
The European Medicines Agency has approved olaparib for women with ovarian cancer who have a BRCA1 or BRCA2 mutation.
Highlights of the year, 2014
2014 has been full of exciting research results for the ICR. We have selected ten of our discoveries from the past year, which we'll publish every day over the next two weeks
Scientists discover way to target rare breast cancer mutation
UK scientists have identified a drug to target a rare breast cancer mutation that helps drive the disease in around 900 of the 50,000 new cases of breast cancer diagnosed in the UK each year.
ICR to collaborate with Merck Serono and Wellcome Trust to co-develop anti-cancer drugs
Merck Serono, The Institute of Cancer Research (ICR), and the Wellcome Trust, London, today announced a co-development and license agreement building on two independent research programs at both the ICR and Merck Serono to identify inhibitors of tankyrase, an enzyme of the poly (ADP-ribose) polymerase family.
ICR researchers focus on smart treatments at leading cancer conference
ICR scientists are making the trip to San Diego this weekend for one of the biggest dates in the cancer calendar – the American Association of Cancer Research (AACR) conference.
Gene prevents breast cancer spread by stopping cells becoming ‘sticky’
Scientists have discovered a gene that prevents the spread of breast cancer by stopping tumour cells from becoming ‘sticky’.
Study leads to new understandings of rare breast cancer type
A study into a unique breast cancer sub-type called micropapillary carcinoma of the breast has given new clues to its genetic make-up.
